Key Documents

View All Documentation

SML0289

Bromfenac sodium

Name: Bromfenac sodium
Brand: SIGMA

≥98% (HPLC), COX1 and COX2 inhibitor, powder

Synonym(s):

2-Amino-3-(4-bromobenzoyl)benzeneacetic acid sodium salt

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₁₅H₁₁BrNNaO₃

CAS Number:

91714-93-1

Molecular Weight:

356.15

UNSPSC Code:

12352200

PubChem Substance ID:

329825297

NACRES:

NA.77

MDL number:

MFCD03701673

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Storage condition:

desiccated

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Product Name

Bromfenac sodium, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

faintly yellow to dark yellow

solubility

H₂O: ≥5 mg/mL

storage temp.

2-8°C

SMILES string

[Na+].Nc1c(CC([O-])=O)cccc1C(=O)c2ccc(Br)cc2

InChI

1S/C15H12BrNO3.Na/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;/h1-7H,8,17H2,(H,18,19);/q;+1/p-1

InChI key

HZFGMQJYAFHESD-UHFFFAOYSA-M

Gene Information

human ... PTGS1(5742), PTGS2(5743)

Related Categories

Bioactive Small Molecule Inhibitors

Bioactive Small Molecules

Application

Bromfenac sodium has been used:

to study its ability to bind to melanin
in the synthesis of bromfenac indolinone standard
to analyze its permeability in porcine conjunctiva

Biochem/physiol Actions

Bromfenac exhibits antipyretic and prostaglandin synthetase inhibiting properties. It has therapeutic properties against the reduction of ocular pain and inflammation in postoperative cataract patients. Bromfenac acts as an effective agent against allergic conjunctivitis. It has the potential to treat acute muscle pain, osteoarthritis, and rheumatoid arthritis.

Bromfenac is a nonsteroidal anti inflammatory drug (NSAID) that inhibits both COX1 and COX2. It is used as an opthalmic analgesic.

Bromfenac is a nonsteroidal anti inflammatory drug (NSAID); COX1 and COX2 inhibitor; opthalmic analgesic.

pictograms

GHS06

signalword

Danger

hcodes

H301

pcodes

P264 - P270 - P301 + P310 - P405 - P501

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

0000488498

0000365928

0000303379

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction.

Ester Carreño et al.

Clinical ophthalmology (Auckland, N.Z.), 6, 637-644 (2012-05-10)

Ophthalmic bromfenac sodium sesquihydrate is a topically applied selective cyclooxygenase (COX)-2 inhibitor. It is similar to amfenac, except for a bromine atom at the C(4) of the benzoyl ring position, which markedly affects its in vitro and in vivo potency

Topical bromfenac 0.09% vs. ketorolac 0.4% for the control of pain, photophobia, and discomfort following PRK.

Neal A Sher et al.

Journal of refractive surgery (Thorofare, N.J. : 1995), 25(2), 214-220 (2009-02-27)

To compare the efficacy of two topical nonsteroidal anti-inflammatory drugs with regards to the control of pain, burning, photophobia, foreign body sensation, and epithelial healing rates in patients who underwent photorefractive keratectomy (PRK). Two hundred twelve eyes were randomized to

NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema.

Keith A Warren et al.

Retina (Philadelphia, Pa.), 30(2), 260-266 (2010-02-23)

The purpose of this study was to evaluate the addition of topical nonsteroidal antiinflammatory drugs (NSAIDs) to intravitreal corticosteroid and antivascular endothelial growth factor injections for the treatment of chronic cystoid macular edema. Thirty-nine patients with chronic pseudophakic cystoid macular

Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot study.

Christina Flaxel et al.

Retina (Philadelphia, Pa.), 32(3), 417-423 (2011-08-25)

To evaluate whether bromfenac eyedrops and ranibizumab intravitreal injections would provide added efficacy over ranibizumab alone. This was a single-site, multiinvestigator, prospective, open-label, interventional, Phase II study of patients with new or recurrent exudative/neovascular age-related macular degeneration. Thirty eyes were

Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain.

Steven M Silverstein et al.

Current medical research and opinion, 27(9), 1693-1703 (2011-07-15)

To evaluate the efficacy and ocular safety of bromfenac ophthalmic solution 0.09% dosed once daily for the treatment of ocular inflammation and pain following cataract extraction with posterior chamber intraocular lens implantation. A total of 455 subjects (455 study eyes:

View All Related Papers

Global Trade Item Number

SKU	GTIN
SML0289-10MG	04061832786469
SML0289-50MG	04061832786476

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service